Status:
COMPLETED
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Cryopyrin-associated Periodic Syndromes (CAPS)
Familial Cold Autoinflam Syn (FCAS)
Eligibility:
All Genders
Brief Summary
The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
Eligibility Criteria
Inclusion
- Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical care
Exclusion
- Local regulations in some locations may exclude patients who receive Ilaris for a non-approved indication
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT01213641
Start Date
November 1 2009
End Date
December 1 2015
Last Update
March 28 2016
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock Allergy and Asthma Clinic
Little Rock, Arizona, United States, 72205
2
Allergy Center at Brookstone
Columbus, Georgia, United States, 31904
3
Rush Presbyterian - St. Lukes Medical Center
Chicago, Illinois, United States, 60612
4
Novartis Investigative site
Bregenz, Austria